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Abstract
Over the past 30 years, Zaire and Sudan ebolaviruses have been responsible for large hemorrhagic fever (HF) outbreaks with
case fatalities ranging from 53% to 90%, while a third species, Co ˆte d’Ivoire ebolavirus, caused a single non-fatal HF case. In
November 2007, HF cases were reported in Bundibugyo District, Western Uganda. Laboratory investigation of the initial 29
suspect-case blood specimens by classic methods (antigen capture, IgM and IgG ELISA) and a recently developed random-
primed pyrosequencing approach quickly identified this to be an Ebola HF outbreak associated with a newly discovered
ebolavirus species (Bundibugyo ebolavirus) distantly related to the Co ˆte d’Ivoire ebolavirus found in western Africa. Due to the
sequence divergence of this new virus relative to all previously recognized ebolaviruses, these findings have important
implications for design of future diagnostic assays to monitor Ebola HF disease in humans and animals, and ongoing efforts
to develop effective antivirals and vaccines.
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Introduction
The family Filoviridae consists of two genera, Marburgvirus and
Ebolavirus, which have likely evolved from a common ancestor [1].
The genus Ebolavirus is comprised of four species, Zaire, Sudan,
Reston and Co ˆte d’Ivoire (Ivory Coast) ebolaviruses, which have, with the
exception of Reston and Co ˆte d’Ivoire ebolaviruses, been associated with
large hemorrhagic fever (HF) outbreaks in Africa with high case
fatality (53–90%) [2]. Viruses of each species have genomes that
are at least 30–40% divergent from one another, a level of
diversity that presumably reflects differences in the ecologic niche
they occupy and in their evolutionary history. Identification of the
natural reservoir of ebolaviruses remains somewhat elusive,
although recent PCR and antibody data suggest that three species
of arboreal fruit bats may be carriers of Zaire ebolavirus [3]. No data
has yet been published to suggest reservoirs for the Sudan, Reston
and Co ˆte d’Ivoire ebolavirus species. However, a cave-dwelling fruit
bat has been recently implicated as a natural host for marburgvirus
[4,5], supporting the hypothesis that different bat species may be
the reservoir hosts for the various filoviruses.
Filovirus outbreaks are sporadic, sometimes interspersed by
years or even decades of no apparent disease activity. The last new
species of ebolavirus was discovered 14 years ago (1994), in Cote
d’Ivoire (Ivory Coast), and involved a single non-fatal case, a
veterinarian who performed an autopsy on an infected chimpan-
zee found in the Tai Forest [6]. No further disease reports have
been associated with Co ˆte d’Ivoire ebolavirus, in contrast to Zaire and
Sudan ebolaviruses which have each caused multiple large outbreaks
over the same time period. Here, we report the isolation and
characterization of a new ebolavirus that was responsible for a
large hemorrhagic fever outbreak in western Uganda. This new
virus, proposed name Bundibugyo ebolavirus, is most closely related,
albeit distantly, to Co ˆte d’Ivoire ebolavirus, which was somewhat
unexpected, given the large geographic distance between the two
countries of origin.
Results/Discussion
In late November 2007 HF cases were reported in the townships
of Bundibugyo and Kikyo in Bundibugyo District, Western
Uganda (Figure 1A). A total of 29 blood samples were initially
collected from suspect cases and sent in two air-transport
shipments to the Centers for Disease Control and Prevention
(CDC) for immediate testing. Evidence of acute ebolavirus
infection was detected in eight specimens using a broadly reactive
ebolavirus antigen capture assay known to cross-react with the
different ebolavirus species [7] and an IgM capture assay based on
Zaire ebolavirus reagents (Table 1). The Ugandan Ministry of Health
was notified on November 28, 2007. These specimens were
negative when initially tested with highly sensitive real-time RT-
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marburgviruses. However, further evidence of acute ebolavirus
infection was obtained using a traditionally less sensitive (relative
to the real-time RT-PCR assays) but more broadly reactive
filovirus L gene-specific RT-PCR assay (1 specimen) (Table 1).
Sequence analysis of the PCR fragment (400 bp of the virus L
gene) revealed the reason for the initial failure of the real-time RT-
PCR assays was that the sequence was distinct from the four
known species of ebolavirus, although it was distantly related to
Cote d’Ivoire ebolavirus. In total, 9 of 29 specimens showed evidence
of ebolavirus infection, and all tests were negative for marburg-
virus (data not shown).
Approximately 70% of the virus genome was rapidly (in less
than 10 days) sequenced from total RNA extracted from a patient
serum (#200706291) using a recently established metagenomics
pyro-sequencing method developed at 454 Life Sciences which
involves successive rounds of random DNA amplification [8].
Using the newly derived draft sequence, a real-time RT-PCR
assay specific for the NP gene of this virus was quickly developed
and evaluated. The assay was shown to have excellent sensitivity
(Table 1), finding positive all the initial six samples that tested
positive by either virus antigen capture (five specimens) or virus
isolation assays (four specimens). The antigen-capture, IgM, IgG
and newly designed real-time PCR assays were quickly transferred
to the Uganda Virus Research Institute during the course of the
outbreak to facilitate rapid identification and isolation of Ebola
cases in the affected area for efficient control of the outbreak. The
outbreak continued through late December, 2007, and resulted in
149 suspected cases and 37 deaths [9].
The entire genome sequence of this virus was completed using a
classic primer walking sequencing approach on RNA from the
reference virus isolate (#811250). The complete genome of the
Co ˆte d’Ivoire ebolavirus was not available, so it too was derived by a
similar combination of random primed pyrosequencing and
primer walking approaches. Acquisition of these sequences
allowed for the first time the phylogenetic analysis of the complete
genomes of representatives of all known species of Ebola and
Marburg viruses. The analysis revealed that the newly discovered
virus differed from the four existing ebolavirus species (Figure 1B),
with approximately 32% nucleotide difference from even the
closest relative, Co ˆte d’Ivoire ebolavirus (Table 2). Similar complete
genome divergence (35–45%) is seen between the previously
characterized ebolavirus species. Bundibugyo ebolavirus is the
proposed name for this newly identified species. This high level
of genetic diversity translates to considerable amino acid
differences in the encoded virus proteins. The virus surface
glycoprotein, which is an important determinant of virus tropism
and pathogenicity, differs between Bundibugyo and Co ˆte d’Ivoire and
Zaire ebolaviruses by over 27 and 35%, respectively at the amino acid
level. Similarly, important virulence factors such as the immuno-
suppressive VP35 protein differ between Bundibugyo and Co ˆte d’Ivoire
and Zaire ebolaviruses by 23 and 25%, respectively. This extent of
divergence will likely be reflected in significant antigenic and
pathogenicity differences among these viruses.
Current human prototype ebolavirus vaccines include Zaire and
Sudan ebolaviruses [10–12]. Cross-protection studies will need to be
done to assess whether vaccine designs will need to incorporate the
Bundibugyo ebolavirus. The unique nature of this virus has other
implications too, including screening of potential antivirals and
pathogenicity studies. Retrospective analysis of case description,
epidemiologic and laboratory data from the Bundibugyo outbreak
are still ongoing, but it is clear that the case fatality (,36%)
associated with Bundibugyo ebolavirus infection is lower than that
observed for Zaire ebolavirus (approx. 80–90%) and Sudan ebolavirus
(approximately 50–55%) [2]. Studies in non-human primates need
to be performed to compare the pathogenicity of these viruses.
This investigation also highlights the power of molecular detection
and characterization tools to quickly identify new pathogens, while
providing a cautionary note regarding sole dependence on
molecular techniques such as real-time PCR assays for detection
of novel agents in biodefense or emerging disease surveillance
programs.
Materials and Methods
Ebolavirus detection and virus isolation
Several diagnostic techniques were used for each sample: (i)
antigen capture, IgG, and IgM assays were performed as
previously described [7,13] (ii) virus isolation attempts were
performed on Vero E6 cells [14] and monitored for 14 days; (iii)
RNA was extracted and tested for Zaire [15] and Sudan ebolavirus
and marburgvirus [4] using real-time quantitative RT-PCR assays
designed to detect all known strains of each respective virus species
[the primers/probe for the Sudan ebolavirus assay were Ebo-
SudBMG 1(+)5 9-GCC ATG GIT TCA GGT TTG AG-39,
EboSudBMG 1(2)5 9-GGT IAC ATT GGG CAA CAA TTC A
and EboSudBMG Probe 59FAM-AC GGT GCA CAT TCT
CCT TTT CTC GGA-BHQ1]; (iv) the conventional RT-PCR
was performed with the filo A/B primer set as previously described
[16] using Superscript III (Invitrogen) according to the manufac-
turer’s instructions. The specimen 200706291 was selected as the
reference sample for further sequence analysis.
Genome sequencing
Pyro-sequencing was carried out utilizing the approach
developed by 454 Life Sciences, and the method described by
Cox-Foster et al., [8]. Subsequent virus whole genome primer
walking was performed as previously described [17] but using the
primers specific for Bundibugyo ebolavirus RT-PCR amplification. In
total, the entire virus genome was amplified in six overlapping RT-
PCR fragments (all primers listed 59 to 39): fragment A (predicted
size 2.7 kb) was amplified using forward-GTGAGACAAAGAAT-
CATTCCTG with reverse-CATCAATTGCTCAGAGATC-
CACC; fragment B (predicted size 3.0 kb) was amplified using
forward-CCAACAACACTGCATGTAAGT with reverse-AGG-
TCGCGTTAATCTTCATC; fragment C (predicted size 3.5 kb)
Author Summary
In this report we describe a newly discovered ebolavirus
species which caused a large hemorrhagic fever outbreak
in western Uganda. The virus is genetically distinct,
differing by more than 30% at the genome level from all
other known ebolavirus species. The unique nature of this
virus created challenges for traditional filovirus molecular
based diagnostic assays and genome sequencing ap-
proaches. Instead, we quickly determined over 70% of the
virus genome using a recently developed random-primed
pyrosequencing approach that allowed the rapid devel-
opment of a molecular detection assay that was deployed
in the disease outbreak response. This draft sequence
allowed easy completion of the whole genome sequence
using a traditional primer walking approach and prompt
confirmation that this virus represented a new ebolavirus
species. Current efforts to design effective diagnostics,
antivirals and vaccines will need to take into account the
distinct nature of this important new member of the
filovirus family.
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PLoS Pathogens | www.plospathogens.org 2 November 2008 | Volume 4 | Issue 11 | e1000212Figure 1. Geographic locations of Ebola HF outbreaks and phylogenetic relationships of representative filoviruses. (A) Map of Africa
showing the sites of all known ebolavirus outbreaks denoted by colored circles for Zaire ebolavirus (yellow), Sudan ebolavirus (green), and Co ˆte d’Ivoire
ebolavirus (red). The expanded map of Uganda shows the location of the communities of Bundibugyo and Kikyo (black circles) in western Uganda,
the site of the recent outbreak of Bundibugyo ebolavirus. Also shown on the Uganda map are the cities of Kampala (capital), Entebbe (international
airport) and Gulu (the site of an outbreak of Sudan ebolavirus in 2000, the largest known Ebola HF outbreak on record). (B) Phylogenetic tree
comparing full-length genomes of ebolavirus and marburgvirus by Bayesian analysis. Posterior probabilities greater than 0.5 and maximum likelihood
bootstrap values greater than 50 are indicated at the nodes.
doi:10.1371/journal.ppat.1000212.g001
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TCCGG with reverse-GTCTTGAGTCATCAATGCCC; frag-
ment D (predicted size 3.1 kb) was amplified using forward-
CCACCAGCACCAAAGGAC with reverse-CTATCGG-
CAATGTAACTATTGG; fragment E (predicted size 3.4 kb)
was amplified using forward-GCCGTTGTAGAGGACACAC
with reverse-CACATTAAATTGTTCTAACATGCAAG and
fragment F (predicted size 3.5 kb) was amplified using forward-
CCTAGGTTATTTAGAAGGGACTA with reverse-GGT AGA
TGT ATT GAC AGC AAT ATC.
The exact 59 and 39 ends of Bundibugyo ebolavirus were
determined by 39 RACE from virus RNA extracted from virus
infected Vero E6 cell monolayers using TriPure isolation reagent.
RNAs were then polyadenylated in vitro using A-Plus poly(A)
polymerase tailing kit (Epicenter Biotechnologies) following the
manufacturer’s instructions and then purified using an RNeasy kit
(Qiagen) following standard protocols. Ten microliters of in vitro
polyadenylated RNA were added as template in RT-PCR
reactions, using SuperScript III One-Step RT-PCR system with
Platinum Taq High Fidelity (Invitrogen) following the manufac-
turer’s protocol. Two parallel RT-PCR reactions using the
oligo(dT)-containing 39RACE-AP primer (Invitrogen) mixed with
1 of 2 viral specific primers, Ebo-U 692(2) ACAAAAAGC-
TATCTGCACTAT and Ebo-U18269(+) CTCAGAAG-
CAAAATTAATGG, generated ,700 nt long fragments contain-
ing the 39 ends of either genomic and antigenomic RNAs. The
resulting RT-PCR products were analyzed by agarose electro-
phoresis, and DNA bands of the correct sizes were purified using
QIAquick Gel Extraction Kit (Qiagen) and sequenced using
standard protocols (ABI).
The nucleotide sequence of the Co ˆte d’Ivoire ebolavirus isolate
RNA was initially determined using the exact same pyro-
sequencing strategy as that used for Bundibugyo ebolavirus described
above. This method generated sequence for approximately 70% of
the entire genome. This draft sequence was then used to design a
whole genome primer walking strategy for filling any gaps and
Table 1. Ebolavirus diagnostic results of initial 29 specimens obtained from Bundibugyo District with numerical specimen
numbers assigned.
Sample No. RT-PCR Ag IgM IgG Virus Isolation Q-RT-PCR Ct
200706288 neg neg neg neg neg neg 40
200706289 neg neg neg neg neg neg 40
200706290 neg neg neg neg neg neg 40
200706291* Pos Pos neg neg Pos Pos 23.64
200706292 neg neg neg neg neg neg 40
200706293 neg neg neg neg neg neg 40
200706294 neg neg neg neg neg neg 40
200706295 neg neg neg neg neg neg 40
200706296 neg neg Pos Pos neg neg 40
200706297 neg neg Pos Pos neg neg 40
200706298 neg Pos Pos Pos neg Pos 34.83
200706299 neg neg Pos Pos neg neg 40
200706300 neg neg neg neg neg neg 40
200706301 neg neg neg neg neg neg 40
200706302 neg Pos Pos neg neg Pos 35.01
200706303 neg neg neg neg neg neg 40
200706304 neg neg neg neg Pos Pos 38.18
200706305 neg neg neg neg neg neg 40
200706306 neg neg neg neg neg neg 40
200706307 neg neg neg neg neg neg 40
200706320 ND Pos neg neg Pos Pos 30.24
200706321 ND neg neg neg neg neg 40
200706322 ND neg neg neg neg neg 40
200706323 ND neg neg neg neg neg 40
200706324 ND neg neg neg neg neg 40
200706325 ND neg neg neg neg neg 40
200706326 ND neg neg neg neg neg 40
200706327 ND Pos neg neg Pos Pos 34.41
200706328 ND neg neg neg neg neg 40
RT-PCR refers to results obtained from conventional PCR using the broadly reactive Filo A/B primers [16]. Ag, IgM, and IgG refer to results from ELISA-based assays [7,13]
with Zaire ebolavirus reagents while virus isolation refers to culture attempts on Vero E6 cells [14]. Q-RT-PCR refers to results obtained using the optimized Bundibugyo
ebolavirus specific real-time RT-PCR assay with cycle threshold (Ct) values of positive (Pos) samples indicated in the far right column.
*Specimen # 200706291 is the clinical sample from which prototype isolate #811250 was obtained.
doi:10.1371/journal.ppat.1000212.t001
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ebolavirus-specific primers were used to generate RT-PCR
fragments, designated A–F, as follows: Fragment A (predicted size
3.0 kb) was amplified using forward-GTGTGCGAATAACTAT-
GAGGAAG and reverse-GTCTGTGCAATGTTGATGAAGG;
Fragment B (predicted size 3.2 kb) was amplified using forward-
CATGAAAACCACACTCAACAAC and reverse-GTTGC-
CTTAATCTTCATCAAGTTC; Fragment C (predicted size
3.0 kb) was amplified using forward-GGCTATAATGAATTT-
CCTCCAG and reverse-CAAGTGTATTTGTGGTCCTAGC;
fragment D (predicted size 3.5 kb) was amplified using forward-
GCTGGAATAGGAATCACAGG and reverse-CGGTAGTC-
TACAGTTCTTTAG; fragment E (predicted size 4.0 kb) was
amplified using forward-GACAAAGAGATTAGATTAGCTA-
TAG and reverse-GTAATGAGAAGGTGTCATTTGG; frag-
ment F (predicted size 2.9 kb) was amplified using forward-
CACGACTTAGTTGGACAATTGG and reverse-CAGACAC-
TAATTAGATCTGGAAG; fragment G (predicted size 1.3 kb)
was amplified using forward-CGGACACACAAAAAGAAWRAA
and reverse-CGTTCTTGACCTTAGCAGTTC; and fragment
H (predicted size 2.5 kb) was amplified using forward-GCACTA-
TAAGCTCGATGAAGTC and reverse-TGGACACACAAA-
AARGARAA. A gap in the sequence contig was located between
fragments C and D and this was resolved using the following
primers to generate a predicted fragment of 1.5 kb: forward-
CTGAGAGGATCCAGAAGAAAG and reverse-GTGTAAG-
CGTTGATATACCTCC. The terminal ,20 nucleotides of the
sequence were not experimentally determined but were inferred
by comparing with the other known Ebola genome sequences.
Bundibugyo ebolavirus real-time RT-PCR assay
The primers and probe used in the Bundibugyo ebolavirus specific Q-
RT-PCR assay were as follows: EboU965(+): 59-GAGAAAAG-
GCCTGTCTGGAGAA-39, EboU1039(2): 59-TCGGGTATT-
GAATCAGACCTTGTT-39 and EboU989 Prb: 59Fam-TTCAAC-
GACAAATCCAAGTGCACGCA-39BHQ1. Q-RT-PCR reactions
were set up using Superscript III One-Step Q-RT-PCR (Invitrogen)
according to the manufacturer’s instructions and run for 40 cycles
with a 58uC annealing temperature.
Phylogenetic analysis
Modeltest 3.7 [18] was used to examine 56 models of nucleotide
substitution to determine the model most appropriate for the data.
The General Time Reversible model incorporating invariant sites
and a gamma distribution (GTR+I+G) was selected using the
Akaike Information Criterion (AIC). Nucleotide frequencies were
A=0.3278, C=0.2101, G=0.1832, T=0.2789, the proportion of
invariant sites=0.1412, and the gamma shape parame-
ter=1.0593. A maximum likelihood analysis was subsequently
performed in PAUP*4.0b10 [19] using the GTR+I+G model
parameters. Bootstrap support values were used to assess
topological support and were calculated based on 1,000 pseudor-
eplicates [20].
In addition, a Bayesian phylogenetic analysis was conducted in
MrBayes 3.2 [21] using the GTR+I+G model of nucleotide
substitution. Two simultaneous analyses, each with four Markov
chains, were run for 5,000,000 generations sampling every 100
generations. Prior to termination of the run, the AWTY module
was used to assess Markov Chain Monte Carlo convergence to
ensure that the length of the analysis was sufficient [22]. Trees
generated before the stabilization of the likelihood scores were
discarded (burn in=40), and the remaining trees were used to
construct a consensus tree. Nodal support was assessed by
posterior probability values ($95=statistical support).
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